Briefing · From the Watchtower
Riboscience to present RBS2418's first overall-survival data at ESMO 2026
Riboscience says its ESMO 2026 poster will carry first Phase 1b overall-survival and immune-activation data for its lead oral ENPP1 inhibitor RBS2418, as monotherapy and in combination in advanced metastatic cancers including MSS colorectal cancer; the figures themselves are not yet public.
What happened
Riboscience, which describes itself as a clinical-stage biotechnology company developing first-in-class immunotherapies, said on 19 October 2026 that it will present Phase 1b data for RBS2418, its lead oral ENPP1 inhibitor, in a poster at the European Society for Medical Oncology Congress 2026 [1]. The poster will carry what the company calls the first overall-survival and immune-activation data from the study, covering RBS2418 both as monotherapy and in combination, in advanced metastatic cancers including microsatellite-stable (MSS) colorectal cancer [1]. The statement came out of Palo Alto, California [1].
That is the full extent of the disclosure. The survival numbers, the immune-activation readouts, the patient counts, the dose levels, and the identity of the combination partner are not in the announcement.
Why it matters
The signal is in what Riboscience chose to lead with. A Phase 1b poster usually reports safety and early response. This one is being pre-announced around overall survival and immune activation [1], the two endpoints a company highlights when it believes the biology is doing something durable rather than transient. Pairing a survival claim with a mechanistic immune-activation claim is the combination a BD team watching the ENPP1 and STING-axis space will open the poster to read.
Showing monotherapy and combination arms in the same dataset also tells you Riboscience wants to argue the oral agent has single-agent activity [1]. And the indication the company put in its own headline is MSS colorectal cancer [1], the setting where an immune-activating oral agent carries the heaviest burden of proof. That is Prognyx's reading of the framing, not a result: no number has been shown.
Track RBS2418
The next move on RBS2418 (readout, FDA/EMA action, deal) by email, the day we publish it.
One email per briefing. Double opt-in, no open tracking. Privacy.
What to watch
The catalyst that matters is ESMO Congress 2026, the venue Riboscience named [1]. Prognyx could not confirm the poster number, session, or presentation date from the release, so the moment the figures become public is the poster itself. Until then there is no survival number, hazard ratio, or biomarker result to act on.
What Prognyx could not verify
Prognyx found no ClinicalTrials.gov record for the RBS2418 Phase 1b trial in public sources as of this briefing, so the trial's current status (recruiting, active, completed, or stopped) is unconfirmed. There is no SEC filing or company release beyond the 19 October statement to corroborate the study design, the combination partner, or Riboscience's funding and ownership. The overall-survival and immune-activation data referenced in the title are described, not disclosed.
The now-what
For a competitor running an ENPP1 or STING-axis program, the move is to put ESMO 2026 on the calendar and brief the clinical team to read the survival and immune-activation data against their own Phase 1 dataset the day it posts. For a BD team, nothing is actionable until the numbers exist: an announcement of data is not data. The decision available today is narrow, whether RBS2418 and oral ENPP1 inhibition earn a place on the watch-list, and on these facts they do.
Verdict: low and informational until ESMO 2026; the window to act opens when the poster is presented, not before.
The Watchtower, by email
The next move on RBS2418, the day it happens.
You have just read a briefing on RBS2418. The next readout, FDA/EMA action or deal reaches you by email the day we publish it. One email per briefing, nothing else.
Double opt-in. Never sold, no open tracking. Privacy.
Questions this briefing answers
What did Riboscience announce about RBS2418?
On 19 October 2026 Riboscience said it will present the first overall-survival and immune-activation data from its Phase 1b study of RBS2418, an oral ENPP1 inhibitor, in a poster at the ESMO Congress 2026, covering the drug as monotherapy and in combination in advanced metastatic cancers including microsatellite-stable colorectal cancer. The release announces the presentation; it does not contain the data.
Are the survival numbers available yet?
No. The survival figures, immune-activation biomarker results, patient numbers, doses, and combination-partner identity are not in the announcement, and Prognyx found no public trial-registry record or company filing to corroborate the trial's status as of this briefing. The figures are expected when the ESMO 2026 poster is presented.
Sources: every claim traces to the primary record
How this briefing was produced: Drafted and audited by the Prognyx engine against the primary sources cited above, then published automatically for clearing the audit threshold set by Rali Filali. Below that threshold, a briefing is not published. The full method.
Get a free sample competitive brief on one of your assets, sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.
Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use.